You have accessJournal of UrologyKidney Cancer: Basic Research & Pathophysiology II1 Apr 2018MP72-16 CREATION OF A RENAL MEDULLARY CARCINOMA MOUSE MODEL: FEASIBILITY AND PRELIMINARY RESULTS AFTER TREATMENT WITH ANTI-NEOPLASTIC AGENTS Barrett McCormick, Matthew Meissner, Lei Wang, Tapaty Maity, Nizar Tannir, Christopher Wood, and Jose Karam Barrett McCormickBarrett McCormick More articles by this author , Matthew MeissnerMatthew Meissner More articles by this author , Lei WangLei Wang More articles by this author , Tapaty MaityTapaty Maity More articles by this author , Nizar TannirNizar Tannir More articles by this author , Christopher WoodChristopher Wood More articles by this author , and Jose KaramJose Karam More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2300AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Renal medullary carcinoma (RMC) is characterized by its highly aggressive nature and poor prognosis. Platinum based agents have only shown modest activity. The objective of this study was to demonstrate creation of a patient derived xenograft (PDX) mouse model of RMC which could be subjected to treatment with anti-neoplastic agents. METHODS After institutional review board approval, severe combined immunodeficiency (SCID) mice (CB17/Icr-Prkdc/IcrIcoCrl, Charles River) were used to create PDX models. From the RMC tissue bank at our institution a patient sample was chosen for xenografts. Patient tumor samples were sliced and implanted in the SCID mouse flank under anesthesia. Short tandem repeat (STR) fingerprinting was used to confirm matching between the human and PDX tissue. The PDX mice were then exposed to various treatment agents (Table 1). Tumors were measured weekly. Treatment continued until a measureable response was noted or tumor growth exceeded the protocol limits. RESULTS Two experiments of tumor implantation and treatment were completed. Each included three treatment arms and a control arm divided with equal numbers of PDX mice (N=25 experiment 1, N=42 experiment 2). Gemcitabine/Cisplatin dosing was reduced by one half during the first experiment due to intolerability. The remaining dosages were unchanged. After a mean treatment duration of 34.5 days, tumor shrinkage from baseline was only observed in the gemcitabine/cisplatin group, including 1/5 (20%) in experiment 1 and 3/6 (50%) in experiment 2 (figure 1) demonstrating a complete response. The other treatment arms showed a response compared to control, but maintained an increase in size from baseline CONCLUSIONS We demonstrate the successful creation of a mouse RMC model with gemcitabine/cisplatin therapy showing excellent treatment efficacy. Further work will include result validation as well as genomic sequencing to detect predictive markers and establish novel therapeutics. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e958 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Barrett McCormick More articles by this author Matthew Meissner More articles by this author Lei Wang More articles by this author Tapaty Maity More articles by this author Nizar Tannir More articles by this author Christopher Wood More articles by this author Jose Karam More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...